Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gwyn Williams

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Eye (London, England)|August 23, 2020
Response to Comment on: Agreement between optometrists and ophthalmologists in the certification for vision impairmentJennifer H Acton, Rebecca Bartlett, Hywel Jones, et al.
Physical Review Letters|March 16, 2007
Realization of a room-temperature spin dynamo: the spin rectification effectY S Gui, N Mecking, X Zhou, et al.
Lancet (London, England)|November 20, 1982
Treatment for renal failure in the West MidlandsJames G Ackers, J S Cameron, C S Ogg, et al.
Advances in Therapy|April 18, 2026
Faricimab in Treatment-Naïve nAMD: Regional UK Real-World ExperienceIan Pearce, Christiana Dinah, Louise Downey, et al.
Conservation Biology : the Journal of the Society for Conservation Biology|June 9, 2016
The value of flexibility in conservation financingGareth D Lennox, Joseph Fargione, Sacha Spector, et al.
Lancet (London, England)|April 6, 1974
Letter: Subnormality at the crossroadsK A Day, V Gorman, R H Gwyn-Williams, et al.
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|November 1, 2024
The unmet need for certification of vision impairment for people accessing a national primary care-based low vision rehabilitation serviceRebecca John, Gwyn Williams, Tim Morgan, et al.
European Journal of Ophthalmology|May 27, 2020
One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumabMarko Lukic, Gwyn Williams, Zaid Shalchi, et al.
European Journal of Ophthalmology|May 21, 2020
Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomesMarko Lukic, Gwyn Williams, Zaid Shalchi, et al.
Eye (London, England)|August 30, 2024
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialistsLouise Downey, Sobha Sivaprasad, Ramandeep Chhabra, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Eye (London, England)|August 23, 2020
Response to Comment on: Agreement between optometrists and ophthalmologists in the certification for vision impairmentJennifer H Acton, Rebecca Bartlett, Hywel Jones, et al.
Physical Review Letters|March 16, 2007
Realization of a room-temperature spin dynamo: the spin rectification effectY S Gui, N Mecking, X Zhou, et al.
Lancet (London, England)|November 20, 1982
Treatment for renal failure in the West MidlandsJames G Ackers, J S Cameron, C S Ogg, et al.
Advances in Therapy|April 18, 2026
Faricimab in Treatment-Naïve nAMD: Regional UK Real-World ExperienceIan Pearce, Christiana Dinah, Louise Downey, et al.
Conservation Biology : the Journal of the Society for Conservation Biology|June 9, 2016
The value of flexibility in conservation financingGareth D Lennox, Joseph Fargione, Sacha Spector, et al.
Lancet (London, England)|April 6, 1974
Letter: Subnormality at the crossroadsK A Day, V Gorman, R H Gwyn-Williams, et al.
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|November 1, 2024
The unmet need for certification of vision impairment for people accessing a national primary care-based low vision rehabilitation serviceRebecca John, Gwyn Williams, Tim Morgan, et al.
European Journal of Ophthalmology|May 27, 2020
One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumabMarko Lukic, Gwyn Williams, Zaid Shalchi, et al.
European Journal of Ophthalmology|May 21, 2020
Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomesMarko Lukic, Gwyn Williams, Zaid Shalchi, et al.
Eye (London, England)|August 30, 2024
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialistsLouise Downey, Sobha Sivaprasad, Ramandeep Chhabra, et al.
Pageof 3